Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Onxeo currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to 1 distinct examiner working within 1 distinct art unit. The concentration of the portfolio indicates that the current prosecution strategy for the company rests with the assigned individual. This interaction with 1 distinct examiner means that the requirements of the assigned official will impact the company's overall patent success. Practitioners should focus on the technical standards prevalent in the Biotechnology & Pharmaceuticals sector to ensure the claims meet the necessary requirements for allowance.
RODRIGUEZ, RAYNA B is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. Monitoring the specific tendencies and past rulings of this examiner is necessary since there are no other active matters to provide a context for the company's standing at the office. Success in this technology area will require a response to the specific concerns raised in this pending action. Legal teams should prioritize understanding the standards of the 1 distinct art unit to effectively address this matter and ensure the application moves toward allowance. Because the busiest examiner is managing 1 pending action, the workload is limited to this matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16078706 | COMBINATION THERAPIES COMPRISING IMMUNO-ONCOLOGY AGENTS AND BELINOSTAT | RODRIGUEZ, RAYNA B | 9d |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16078706 | COMBINATION THERAPIES COMPRISING IMMUNO-ONCOLOGY AGENTS AND BELINOSTAT | RODRIGUEZ, RAYNA B | 1628 | §103 | Final Rejection | 9d | Pending | Aug 22, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOnxeo has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Rayna B Rodriguez has the most, with 1 of Onxeo's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
